Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential SGN-35 Therapy With AVD for Older Patients With Untreated Hodgkin Lymphoma
NCT01476410Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Nov 2011
- Primary completion
- Apr 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in Hodgkin lymphoma (HL), sponsored by Northwestern University. Started Nov 2011; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01476410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01476410.